IL-4 and IL-13 receptor signaling from 4PS to insulin receptor substrate 2: There and back again, a historical view
JournalFrontiers in Immunology
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractIn this historical perspective, written in honor of Dr. William E. Paul, we describe the initial discovery of one of the dominant substrates for tyrosine phosphorylation stimulated by IL-4. We further describe how this "IL-4-induced phosphorylated substrate" (4PS) was characterized as a member of the insulin receptor substrate (IRS) family of large adaptor proteins that link IL-4 and insulin receptors to activation of the phosphatidyl-inositol 3' kinase pathway as well as other downstream signaling pathways. The relative contribution of the 4PS/IRS pathway to the early models of IL-4-induced proliferation and suppression of apoptosis are compared to our more recent understanding of the complex interplay between positive and negative regulatory pathways emanating from members of the IRS family that impact allergic responses. Copyright 2018 Keegan, Zamorano, Keselman and Heller.
SponsorsFirst and foremost, we acknowledge the many contributions of Bill Paul to the initial discovery and characterization of 4PS and IRS control of IL-4-induced responses, and for providing mentoring and guidance for studies spanning the past 28 years. We further acknowledge the many NIH colleagues including Jacalyn H. Pierce, Ling-Mei Wang, Keats Nelms, John J. Ryan, Cyndy Watson, Jane Hu-Li, Carol Adler, Warren Leonard, and John J. O'Shea who provided expertise and critical input to the effort. We also acknowledge members of our laboratories who contributed directly to 4PS/IRS projects including Helen Wang, Li Li, Ann Kelly-Welch, Greg Carey, Holly Porter, Preeta Dasgupta, Nicolas Dorsey, Xiulan Qi, Sarah McCormick, and Kristi Warren. Finally, we acknowledge the many other investigators in the field whose work continues to illuminate the complex role of IRS family members in the regulation of allergic disease. This work was supported by the National Institutes of Health awards R56AI122631 (ADK) and R01HL124477 (NH), the United States Veteran's Administration Merit Award I01 BX001850 (ADK), and the Junta de Extremadura (Spain) GR15115 (JZ).
IL-4-induced phosphorylated substrate
Insulin receptor substrate
Interleukin-13 receptor alpha1 subunit
Interleukin-4 receptor a
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85047003271&doi=10.3389%2ffimmu.2018.01037&partnerID=40&md5=99f5be378f222d6ec5d064c1a94414b7; http://hdl.handle.net/10713/8945
Showing items related by title, author, creator and subject.
A negative allosteric modulator for α5 subunit- containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in miceZanos, P.; Nelson, M.E.; Highland, J.N. (Society for Neuroscience, 2017)New antidepressant pharmacotherapies that provide rapid relief of depressive symptoms are needed. The NMDA receptor antagonist ketamine exerts rapid antidepressant actions in depressed patients but also side effects that complicate its clinical utility. Ketamine promotes excitatory synaptic strength, likely by producing high-frequency correlated activity in mood-relevant regions of the forebrain. Negative allosteric modulators of GABA-A receptors containing α5 subunits (α5 GABA-NAMs) should also promote high-frequency correlated electroencephalogram (EEG) activity and should therefore exert rapid antidepressant responses. Because α5 subunits display a restricted expression in the forebrain, we predicted that α5 GABA-NAMs would produce activation of principle neurons but exert fewer side effects than ketamine. We tested this hypothesis in male mice and observed that the α5 GABA-NAM MRK-016 exerted an antidepressant-like response in the forced swim test at 1 and 24 h after administration and an anti-anhedonic response after chronic stress in the female urine sniffing test (FUST). Like ketamine, MRK-016 produced a transient increase in EEG γ power, and both the increase in γ power and its antidepressant effects in the forced swim test were blocked by prior administration of the AMPA-type glutamate receptor antagonist 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX). Unlike ketamine, however, MRK-016 produced no impairment of rota-rod performance, no reduction of prepulse inhibition (PPI), no conditioned-place preference (CPP), and no change in locomotion. α5 GABA-NAMs, thus reproduce the rapid antidepressant-like actions of ketamine, perhaps via an AMPA receptor (AMPAR)-dependent increase in coherent neuronal activity, but display fewer potential negative side effects. These compounds thus demonstrate promise as clinically useful fast-acting antidepressants. Copyright 2017 Zanos et al.
Inhibition of alpha7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine-conditioned place preference and associated changes in AMPA receptor bindingWright, V.L.; Georgiou, P.; Bailey, A. (Blackwell Publishing Ltd, 2018)Recurrent relapse is a major problem in treating opiate addiction. Pavlovian conditioning plays a role in recurrent relapse whereby exposure to cues learned during drug intake can precipitate relapse to drug taking. α7 nicotinic acetylcholine receptors (nAChRs) have been implicated in attentional aspects of cognition and mechanisms of learning and memory. In this study we have investigated the role of α7 nAChRs in morphine-conditioned place preference (morphine-CPP). CPP provides a model of associative learning that is pertinent to associative aspects of drug dependence. The α7 nAChR antagonist methyllycaconitine (MLA; 4 mg/kg s.c.) had no effect on the acquisition, maintenance, reconsolidation or extinction of morphine-CPP but selectively attenuated morphine-primed reinstatement of CPP, in both mice and rats. Reinstatement of morphine-CPP in mice was accompanied by a selective increase in [3H]-AMPA binding (but not in [3H]-MK801 binding) in the ventral hippocampus that was prevented by prior treatment with MLA. Administration of MLA (6.7 μg) directly into the ventral hippocampus of rats prior to a systemic priming dose of morphine abolished reinstatement of morphine-CPP, whereas MLA delivered into the dorsal hippocampus or prefrontal cortex was without effect. These results suggest that α7 nAChRs in the ventral hippocampus play a specific role in the retrieval of associative drug memories following a period of extinction, making them potential targets for the prevention of relapse. Copyright 2018 The Authors.
Role of the Type I IL-4 Receptor (Type I IL-4R) and Insulin Receptor Substrate (IRS)-2 in Allergic Lung InflammationDasgupta, Preeta; Keegan, Achsah D. (2011)TH2 cytokines, IL-4 and IL-13, play critical roles in allergic lung inflammation and drive alternative activation of macrophages (AAM). They signal through the Type I and Type II receptor (R) complexes. Although both cytokines share receptor subunits, they have differential roles in asthma pathogenesis: IL-4 regulates TH2 cell differentiation, while IL-13 regulates airway hyperreactivity and mucus production. IL-4 signaling through the Type I IL-4R predominantly activates Insulin Receptor Substrate (IRS)-2 and induces AAM gene expression in vitro; AAM can enhance allergic inflammation. The contributions of the Type I and Type II receptors in modulating features of airway inflammation in vivo, however, are unclear. We hypothesized that absence of signaling through the Type I IL-4R and IRS-2 would lead to reduced airway inflammation. Since TH2 differentiation plays a pivotal role in asthma, we first developed a mouse model of this disease using in vivo-primed T cells. To test our hypothesis, we adoptively transferred wild-type OVA-primed CD4+ T cells into Rag2-/-, or gamma c (γc)-/- mice, which lack the Type I IL-4R. Surprisingly, we found that γc-/- mice developed increased lung inflammation and eosinophilia upon OVA challenge when compared to Rag2-/- mice. Lung epithelial cells in both mouse strains expressed AAM proteins FIZZ1 and YM1, while macrophages expressed only YM1. However, the number of FIZZ1+ or YM1+ airways was significantly higher in γc-/- mice. In the γc deficient environment, CD4+ T cells produced greater quantities of TH2 cytokines and IFNγ. These results suggest that in absence of the Type I R, the Type II R can mediate allergic responses when WT TH2 effectors are provided. IFNγ can enhance established TH2 responses, explaining the exaggerated asthma phenotype seen in γc-/- mice. Studies in IRS-2-/- mice demonstrated a negative regulatory role for this protein in allergic airway disease. These mice developed enhanced pulmonary inflammation with significantly increased recruitment of eosinophils and macrophages in comparison to WT mice. Additionally, increased AAM gene/protein expression was detected in macrophages lacking IRS-2 in vitro and in vivo. In conclusion, this study delineated the relative contribution of the Type I R versus the Type II R in asthma pathogenesis.